Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.65
- Piotroski Score 2.00
- Grade Outperform
- Symbol (BCRX)
- Company BioCryst Pharmaceuticals, Inc.
- Price $7.85
- Changes Percentage (-4.15%)
- Change -$0.34
- Day Low $7.83
- Day High $8.24
- Year High $8.88
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $16.00
- High Stock Price Target $25.00
- Low Stock Price Target $7.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.07
- Trailing P/E Ratio -5.9
- Forward P/E Ratio -5.9
- P/E Growth -5.9
- Net Income $-226,539,000
Income Statement
Quarterly
Annual
Latest News of BCRX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ...
Helen Thackray aims to demonstrate the effectiveness of Netherton syndrome treatment by focusing on skin penetration, target binding, and functional cure potential. Charlie Gayer expects continued ORL...
By Yahoo! Finance | 1 week ago -
BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript
BioCryst Pharmaceuticals provided insights in their Q3 2024 earnings call. The company emphasized continued growth in Orladeyo revenue and confidence in reaching sustainable profitability. They discus...
By Yahoo! Finance | 1 week ago -
Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) The Top Stock With Improving Technical Ratings According To Piper Sandler?
Piper Sandler's Top Technical Stock Picks include BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ranking 14th. Recent market swings were influenced by economic data, geopolitical tensions, and job repor...
By Yahoo! Finance | 1 month ago
